-
First-in-class immunomodulators are reacquired to fda fast-track for the treatment of scleroderma-related interstitial lung disease
Time of Update: 2022-09-20
S. FDA has granted the company's primary drug candidate, efzofitimod, for the treatment of systemic sclerosis (SSc, also known as scleroderma) related interstitial lung disease (ILD) fast-track qualification, after the FDA granted efzofitimod a fast-track qualification for the treatment of pulmonary sarcoidosis.
-
Lupus immunomodulation research based on large cohort and single-cell RNA sequencing technology
Time of Update: 2022-09-07
To accompany the lupus advocacy, we share here two innovative studies that have brought new insights into systemic lupus erythematosus (SLE) to understand genomic differences in circulating immune cells and cell-type-specific genes Express the relationship between features .
-
JGH: Immunomodulators with vedolizumab have potential benefit in maintaining ulcerative colitis remission
Time of Update: 2022-02-17
Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis.
Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis.
-
Sci Adv: A New Mechanism of Multiple Myeloma's Resistance to Immunomodulators
Time of Update: 2021-06-18
Teru Hideshima as co-first authors) published a titled ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow in Science Advances.
The paper described in detail the role and mechanism of ERK signaling pathway in myeloma drug resistance caused by the bone marrow microenvironment of multiple myeloma .
-
"Gospel" for patients with refractory gout——Pegloticase + immunomodulator
Time of Update: 2021-05-22
Studies have shown that in patients with refractory gout, the combined application of immunomodulators and polyethylene glycol recombinant uricase can significantly increase the response rate of patients.
-
Immunomodulation vaccine sealed FDA breakthrough therapy in combination with anti-PD-1 antibodies to treat melanoma
Time of Update: 2021-01-23
The immunomodulation vaccine developed by the T-win technology platform directly kills specific T-cell responses to targeted immunosuppressive and tumor cells (Photo: IO Biotech.com) This breakthrough therapy was awarded based on data from Phase 1/2 clinical trials, with 30 metastases receiving IO102, IO103 and anti-PD-1 antibody therapy.
-
Clin Nutrition: Effects of immunomodulated nutrients on infection complications in patients
Time of Update: 2021-01-12
researchers assessed the risk factors for complications of postoperative infection and the effects of preoperative immunotrophic nutrition in patients with low SMI who received PD before surgery.
-
Cell: The lymph nodes are governed by a unique resurgency neuron with immunomodulation potential
Time of Update: 2021-01-03
In the new study, the researchers used a variety of methods, including advanced imaging, retrograde tracing, single-cell RNA sequencing, and photogenetics, to map the connections between neurons, immune cells and other types of cells in the lymph nodes of mice.
-
Nat Commun: Inhibits special immunomodulation signaling path pathps in breast cancer or is expected to promote the body's efficient anti-tumor immune response
Time of Update: 2020-12-26
In a recent study published in the international journal Nature Communications, scientists from institutions such as Spain's National Cancer Research Centre found that RANK signaling paths may be a key candidate to help regulate the immune response in breast tumors; : CC0 Public Domain researchers say inhibiting rank proteins may promote the recruitment of immune cells in mouse models and body tumors in breast cancer patients.
-
Immunomodulation vaccine! FDA grants IO102/IO103 breakthrough drug eligibility: 79% overall
Time of Update: 2020-12-26
, the company announced that the U.S. Food and Drug Administration (FDA) has granted IO102 and IO103 combined anti-PD-1 monoantial combination therapy to treat non-removable/metastasis melanoma patients with breakthrough drug eligibility (BTD).
-
The source of Chinese medicine, Akolading: New progress has been made in the study of the mechanism of anti-tumor action of small molecule immunomodulation
Time of Update: 2020-12-23
The study provides an important molecular biological basis for further study of Acolatin's anti-inflammatory and immunomodulation signaling path, anti-tumor mechanism and combination drug use, and is expected to provide more innovative ideas and options for clinical research on the unique immunomodulation and joint treatment of tumor patients by Acolatin, a small molecule of Chinese medicine.
-
Sci Adv: Deng Hongyu's team revealed the molecular mechanisms of herpes virus immune escape and host natural immunomodulation
Time of Update: 2020-12-11
the study identified pphosphatase PPM1G, a host protein that negatively regulates the natural immune responses of STING and MAVS, and analyzed the molecular mechanism of the Kaposi sarcoma-related herpes virus (KSHV) using the interstitrin ORF33 to hold PPM1G for immune escape.
-
Immunomodulation of Plant Function by In Vitro Selected Single-Chain Fv Intrabodies
Time of Update: 2020-11-16
This needs basic prerequisites to be successfully applied as resources and techniques to isolate specific recombinant antibodies with sufficient binding parameters to bind and to block even low-concentrated targets or to compete successfully with substrates and ligands.
-
The National Institutes of Health (NIH) has begun large-scale clinical trials to test the effectiveness of immunomodulants in the treatment of COVID-19.
Time of Update: 2020-10-27
The National Institutes of Health (NIH) has launched a Phase III clinical trial to assess the safety and effectiveness of three immunomodulants in treating COVID-19 inpatients.
Collins, director of the National Institutes of Health, said, "Immune regulators may provide another treatment in the ACTIV treatment kit." .
-
JCC: A combination of biologics and immunomodulants is superior to monotherapy and reduces the risk of complications associated with inflammatory bowel disease.
Time of Update: 2020-10-13
multivariate Cox proportional risk modeling is used to assess the association between target results and receiving combined therapy and anti-TNF monotherapy.
analysis of the real-world IBD patient database, researchers found that a combined treatment of biologics and immunomodulants reduced the likelihood of failure in CD and UC patients.